Search 

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.

Today, the portfolio consists of 35 projects, of which 14 are pharmaceuticals in clinical development, 7 in phase I and 7 in phase II

In the active portfolio, Karolinska Development has four projects in oncology, whereof three in clinical development, four clinical development programs in skin disease and wound healing, three projects in women’s health, two in infection, two in CVD, CNS and inflammation respectively and one in opthalmology. Furthermore, 10 technology programs in the areas of implants, diagnostics, formulation and medical equipment. Several are open for licensing and co-development discussions.

We are also looking for breakthrough investment opportunities in the areas of Life Sciences (pharma/biotech, medtech)

Keystone Nano (KN) is a developing two nanotechnology platforms to solve problems in the treatment of cancer. Both the Ceramide NanoLiposome (CNL) and the NanoJacket (NJ) precisely deliver therapies to tumors and address a $50 billion cancer therapeutic market where single products routinely exceed a billion in sales. KN’s technology was licensed from Penn State, and is distinct from all technology in development and has substantial technological advantages.  KN technology is an advanced stage of development is supported by considerable intellectual property and a successful multi-disciplinary commercialization team.

KN also creates custom nanoparticles for client companies designed to allow the creation of new products of value with highly unique features.  KN has worked with a wide range of pharmaceutical clients in this manner, and can do so in a milestone based manner.

Kimberly-Clark has developed an innovative transdermal drug delivery technology for Biologics.  The Biologic Transdermal System is designed to deliver large molecular weight biologics (demonstrated up to 150,000 Daltons) without a pump or other secondary device.   Kimberly-Clark has a rich heritage of providing innovative, high quality products for both consumer and B2B markets, including its $1.5 billion healthcare division that manufactures and markets a broad range of medical devices and medical supplies.

COMPANY PRESCRIPTION;

Kissei America, Inc is the US subsidiary of Kissei Pharma, one of the Japanese medium-sized pharma companies spending about 20% of revenue to its R&D effort. 

 Kissei is actively seeking for in-licensing, out-licensing and other business development opportunities for new drugs. 

For in-licensing, Kissei's primary focus is the territory of Japan and the therapeutic fields of urology, dialysis management/kidney disease, women's health, opthalmology and certain diseases with unmet medical needs.

For out-licensing, Kissei is actively seeking partners for several new chemical entities for the territory outside Japan.   Such out-licensing opportunities include agents for endometriosis/fibroid, diabetes, Parkinson's disease, gout/hyperuricemia and kidney stone in various stage of development.

PIPELINE PRODUCT;

1.       NAME ; Mitiglinide

DESCRIPTION     ; Mitiglinide is a short-acting insulin secretagogue for type II diabetes.  The  

                               agent has been already on the market in Japan and some Asian countries. 

                               The product is available for licensing in certain countries outside Asian

                                countries.

PHASE                    ; Market

INDICATION        ; Type II diabetes

2.       NAME ; Remoglifozin

DESCRIPTION     ; Remogliflozin is an SGLT2 inhibitor available for licensing in certain

                                countries.

PHASE                    ; Phase ll, lla, llb

INDICATION       ; Diabetes

3.       NAME; KUL-7211

DESCRIPTION     ; KUL-7211 is a beta 2/3 dual agonist, targeting the facilitation of kidney   

                                stone passage, available for licensing.

PHASE                   ;  Phase ll, lla, llb

INDICATION       ;  Kidney Stone

4.       NAME ; KLH-2109

DESCRIPTION         ; KLH-2109 is on oral GnRH antanogist available for licensing

PHASE                       ; Phase ll, lla, llb

INDICATION           ; Endometriosis, Uterine Fibroids

5.       NAME ; KGA-3235

DESCRIPTION         ; KGA-3235 is an SGLT1 inhibitor available for licensing in certain Asian

                                    countries.

PHASE                       ; Phase l

INDICATION           ;  Diabetes

6.       NAME ; KOM-1962

DESCRIPTION         ; KOM-1962 is a novel and improved COMT inhibitor available for

                                    licensing.

PHASE                       ; Preclinical

INDICATION           ; Parkinson’s Disease

7.       NAME ; KUX-0511

DESCRIPTION         ; KUX-0511 is the agent to be developed for gout and hyperuricemia

                                    through  decreasing  formation of uric acid and uricosuric effect, and                      

                                    available for  licensing.

PHASE                       ; Phase l

INDICATION           ; Gout and Hyperuricemia

Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.

Areas of Interest

•      Cardiovascular

•      Metabolic Syndromes

•      Pain Management

•      Auto-inflammatory

•      Gastroenterological

Partnership Structures

•      Co-development

•      Co-commercialization

•      Licensing

•      Across all stages of development & commercialization